GIP/GLP-1Investigational · Phase 3

VK2735

Dual GIP and GLP-1 receptor agonist. Once weekly (injectable); once daily (oral).

VK2735 (investigational)·Viking Therapeutics

Catalog reviewed Sep 30, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

What to know about VK2735

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

FDA shortage report: In development
Investigational. Not FDA-approved.
Route & frequency: Once weekly (injectable); once daily (oral)

Indications

Investigational uses

VK2735 (investigational)

Obesity; type 2 diabetes (investigational)

Obesity (investigational)Type 2 diabetes (investigational)

An investigational dual agonist of the GIP and GLP-1 receptors, the same validated class as approved tirzepatide, in development as both a once-weekly subcutaneous injection and a once-daily oral tablet.

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

No approved label (investigational)

VK2735 is investigational. See its registered studies below. Search DailyMed.

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.

Evidence

Clinical trials

8 registered trials indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.